Business Description
Quince Therapeutics is a drug development company focused on creating treatments for rare and debilitating conditions, with its primary program targeting ataxia-telangiectasia, a serious inherited neurological disorder that affects children. The company's core technology works by loading medication directly into a patient's own red blood cells using an automated system, which helps deliver treatment more precisely. Founded in 2012 and based in South San Francisco, California, the company was previously called Cortexyme Inc. before rebranding in 2022.
